372 related articles for article (PubMed ID: 28088573)
1. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
2. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review).
Wang X; Chen M; Zhou J; Zhang X
Int J Oncol; 2014 Jul; 45(1):18-30. PubMed ID: 24789222
[TBL] [Abstract][Full Text] [Related]
3. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
[TBL] [Abstract][Full Text] [Related]
4. Targeting HSP90 for cancer therapy.
Mahalingam D; Swords R; Carew JS; Nawrocki ST; Bhalla K; Giles FJ
Br J Cancer; 2009 May; 100(10):1523-9. PubMed ID: 19401686
[TBL] [Abstract][Full Text] [Related]
5. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy.
Lin TY; Guo W; Long Q; Ma A; Liu Q; Zhang H; Huang Y; Chandrasekaran S; Pan C; Lam KS; Li Y
Theranostics; 2016; 6(9):1324-35. PubMed ID: 27375782
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hsp90 for the treatment of cancer.
Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
[TBL] [Abstract][Full Text] [Related]
7. [Thermosensitization of tumor cells with inhibitors of chaperone activity and expression].
Kudriavtsev VA; Makarova IuM; Kabakav AE
Biomed Khim; 2012; 58(6):662-72. PubMed ID: 23350198
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
9. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
10. Targeting heat shock proteins in cancer.
Jego G; Hazoumé A; Seigneuric R; Garrido C
Cancer Lett; 2013 May; 332(2):275-85. PubMed ID: 21078542
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
12. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
13. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
15. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P
J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
18. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
19. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
20. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]